Patent ID: 11905273
Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC C

Claim 0:
1. A compound having Formula II,, wherein
R1 is selected from —(C2-C8 alkyl)—OH, —(C2-C8 alkyl)—NH2, —O—(C2-C8 alkyl)—OH, —O—(C2-C8 alkyl)-NH2, —NH—(C1-C8 alkyl)—OH, —NH(C1-C8 alkyl)—NH2, —NH—Cy1, —NH—Cy2, —O—Cy1, —O—Cy2, —NHCH2—Cy1, —NHCH2—Cy2; —OCH2—Cy3, and —OCH2—Cy2; wherein Cy1, when present is an amino C3-C8 cycloalkyl or hydroxy C3-C8 cycloalkyl, and wherein Cy1 is substituted with 0, 1, 2, or 3 groups independently selected from halogen, C1-C4 alkyl, C1-C4 monohaloalkyl, and C1-C4 polyhaloalkyl; and wherein Cy3, when present, is a C2-C7 heterocycloalkyl comprising at least one oxygen or nitrogen atom, and wherein Cy2 is substituted with 0, 1, 2, or 3 groups independently selected from halogen C1-C4 alkyl, C1-C4 monohaloalkyl, and C1-C4 polyhaloalkyl;
R2 is selected from Ar2, -A1-A2-Ar2, and —C≡C-Ar2; wherein each of A1 and A2, when present is independently selected from O, NH, and CH2, provided that each of A1 and A2 is not simultaneously O; and wherein Ar2 is selected from aryl and heteroaryl, and wherein Ar2 is substituted with 0, 1, 2, or 3 groups independently selected from halogen —CN, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, cyclopropyl, —NHCOR20, —NHSO2R20, —CONR21aR21b, —SO2NR21aR21b, —CO2H, and tetrazole;
R3 is selected from hydrogen, —(C2-C8 alkyl)—OH, —(C2-C8 alkyl)—NH2, —O—(C2-C8 alkyl)—OH, —O—(C2-C8 alkyl)-NH2, —NH—(C1-C8 alkyl)—OH, and —NH(C1-C8 alkyl)—NH2, —NH—Cy3, —NH—Cy4, —O—Cy3, —O—Cy4, —NHCH2—Cy3, —NHCH2—Cy4; —OCH2—Cy3, and —OCH2—Cy3; and —OCH2—Cy4; wherein Cy3, when present is an amino C3-C8 cycloalkyl or hydroxy C3-C8 cycloalkyl, and wherein Cy1 is substituted with 0, 1, 2, or 3 groups independently selected from halogen, C1-C4 alkyl, C1-C4 monohaloalkyl, and C1-C4 polyhaloalkyl; and wherein Cy4, when present, is a C2-C7 heterocycloalkyl comprising at least one oxygen or nitrogen atom, and wherein Cy4 is substituted with 0, 1, 2, or 3 groups independently selected from halogen C1-C4 alkyl, C1-C4 monohaloalkyl, and C1-C4 polyhaloalkyl;
R4 is selected from hydrogen and C1-C4 alkyl;
Ar1 is selected from C1-C7 cycloalkyl, or C5-C7 cycloalkenyl, and wherein Ar2 is substituted with 0, 1, 2, or 3 groups independently selected from halogen —CN, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, —NHCOR20, —NHSO2R20, —CONR21aR21b, —SO2NR21aR21b, —CO2H, and tetrazole;
each occurrence of R20, when present, is independently selected from C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3 polyhaloalkyl, and cyclopropyl;
each occurrence of R21a and R21b, when present, is independently selected from hydrogen, C1-C3 alkyl, C1-C3 monohaloalkyl, C1-C3, and cyclopropyl;
or a pharmaceutically acceptable salt thereof.